Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | TNFSF11 | O14788 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996474 | 0.84 | NR4A2 (0.64) | HDAC1HDAC2NR4A2HTR3ACA12 | |
| SCHEMBL408830 | 0.83 | HDAC1 (0.49) | HDAC1HDAC2CREBBPLMNARORC | |
| Hydrochloric Acid SCHEMBL441849 | 0.82 | HDAC1 (0.48) | HDAC1HDAC2CREBBPLMNARORC | |
| SCHEMBL27381201 | 0.79 | CA1 (0.59) | HDAC1HDAC2CA12CA1CA2 | |
| SCHEMBL10321788 | 0.79 | NR4A2 (0.64) | HDAC1HDAC2NR4A2HTR3ACA12 | |
| SCHEMBL27381191 | 0.78 | HDAC1 (0.56) | HDAC1HDAC2NR4A2LMNARORC | |
| SCHEMBL579555 | 0.76 | NR4A2 (0.65) | HDAC1HDAC2NR4A2HTR3ACA12 | |
| SCHEMBL31601057 | 0.76 | NR4A2 (0.69) | HDAC1HDAC2NR4A2HTR3ACA12 | |
| SCHEMBL11553625 | 0.76 | NR4A2 (0.69) | HDAC1HDAC2NR4A2HTR3ACA12 | |
| SCHEMBL13335120 | 0.76 | NR4A2 (0.69) | HDAC1HDAC2NR4A2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | HDAC1 100/4885HDAC2 256/4885NR4A2 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.